Workshop A Tuesday, June 25

9:00 am - 12:00 pm
Developing Efficacious T Cell Engager Modalities for Targeting Solid Tumors

T cell engagers targeting solid tumors need to achieve an efficacious exposure at a distant tumor site, while at the same time avoiding toxicities caused by high exposures in normal tissues. In contrast, in hematologic malignancies, T cell engagers generally target tumors cells that are in or close to the  circulatory system, making it easier to achieve a tolerated therapeutic dose.
Attend this workshop to:
  • Discuss design consideration for the development of T cell engagers for solid tumors
  • Focus on target selection, tumor penetration, half-life extension and stability of the modality under physiological conditions
Workshop Leaders: Holger Wesche, CSO, Harpoon Therapeutics Inc. & Rick Austin, Senior Director of Biology, Harpoon Therapeutics Inc.

Workshop B Tuesday, June 25

1:00 pm - 4:00 pm
Analyzing the Importance of Target Selection in Early Cell Engager Development

The choice of target in the cell engager space is paramount. Careful analysis of target characteristics, including expression profile and accessibility can aid the decision making process to find targets which will have maximal efficacy without compromising safety. Attend this workshop to verify the importance of target selection in early development.

In this workshop we will:

  • Hear case-by-case examples of the impacts of target selection on the efficacy and safety of cell engager drugs
  • Learn what characteristics of a target impact potential for success
  • Explore how specific binding modes or molecule formats can impact potency and efficacy

Workshop Leader: Julie Bailis, Principal Scientist, Amgen